Fluorescent silica-based nanoparticles
The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as polyethylene glycol) (PEG) The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo The nanoparticle may further be conjugated to a ligand capable of binding to a cellular component associated with the specific cell type, such as a tumor marker A therapeutic agent may be attached to the nanoparticle Radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle to permit the nanoparticle to be detectable by various imaging techniques.
1. A fluorescent silica-based nanoparticle comprising:
a silica-based core;
a fluorescent compound within the core;
a silica shell surrounding at least a portion of the core;
an organic polymer attached to the nanoparticle, thereby coating the nanoparticle; and a plurality of arginylglycylaspartic acid (RGD)-containing peptide ligands no greater than twenty in number attached to the polymer-coated nanoparticle,
wherein the nanoparticle has a diameter from 1 nm to 8 nm as measured by dynamic light scattering.
2. The nanoparticle of claim 1 , wherein the organic polymer comprises polyethylene glycol.
3. The nanoparticle of claim 2 , wherein the polyethylene glycol is attached to a silica surface of the nanoparticle via an amino-silane coupled to an activated ester group on the organic polymer leading to an amide bond.
4. The nanoparticle of claim 2 , wherein the nanoparticle is coated with maleimido-terminated polyethylene glycol chains for attachment of the plurality of RGD-containing peptide ligands.
5. The nanoparticle of claim 1 , wherein a plurality of RGD-containing peptide ligands no greater than ten in number are attached to the polymer-coated nanoparticle.
6. The nanoparticle of claim 1 , wherein the RGD-containing peptide is cyclic.
7. The nanoparticle of claim 6 , wherein the nanoparticle is coated with maleimido-terminated polyethylene glycol chains for attachment of the one or more cyclic RGD-containing peptide ligands, and wherein at least one cyclic RGD-containing peptide ligand is attached to a maleimido-terminated polyethylene glycol chain via a thiol group of a cysteine linker.
8. The nanoparticle of claim 1 , wherein the RGD-containing peptide ligands are labeled with a radionuclide.
9. The nanoparticle of claim 8 , wherein the RGD-containing peptide ligands are labeled with the radionuclide via a tyrosine (Y) linker.
10. The nanoparticle of claim 1 , further comprising a therapeutic agent.
11. The nanoparticle of claim 1 , wherein the fluorescent compound is Cy5.
12. The nanoparticle of claim 1 , wherein the fluorescent compound is Cy5.5.
13. The nanoparticle of claim 1 , wherein the arginylglycylaspartic acid (RGD)-containing peptide ligands are cyclic arginylglycylaspartic acid (RGD) or cyclic arginylglycylaspartic acid comprising tyrosine (RGDY).